MLLT11抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P02072(MLLT11 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The MLLT11 antibody is designed to target the MLLT11 protein, also known as ELL-associated factor 2 (EAF2), a component of the super elongation complex (SEC) that regulates transcriptional elongation by RNA polymerase II. MLLT11 plays a critical role in hematopoiesis and has been implicated in chromosomal translocations, particularly with the MLL (Mixed-Lineage Leukemia) gene in acute leukemias. These translocations generate oncogenic fusion proteins that disrupt normal transcriptional regulation, contributing to leukemogenesis.

MLLT11 is involved in modulating chromatin structure, histone acetylation, and transcriptional activation, often interacting with other elongation factors like ELL and P-TEFb. Its dysregulation is associated with aggressive cancer phenotypes, including cell proliferation and apoptosis resistance. Antibodies against MLLT11 are widely used in research to study its expression patterns, subcellular localization, and interactions in both normal and malignant cells. They are essential tools in techniques such as Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP), aiding in the exploration of its role in transcriptional control and disease mechanisms.

Research using MLLT11 antibodies has provided insights into its dual roles as a tumor suppressor in certain contexts and an oncogenic collaborator in others, highlighting its therapeutic potential in targeting SEC-dependent cancers. These studies underscore its relevance in understanding hematologic malignancies and developing targeted therapies.